Right ventricular (RV) diastolic function in patients with pulmonary hypertension (PH) due to chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 26s Year: 2002
Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008
6MWD in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 464s Year: 2003
Sitaxsentan improves 6MW and hemodynamics in patients with pulmonary arterial hypertension (PAH) related to connective tissue disease (CTD) Source: Eur Respir J 2005; 26: Suppl. 49, 564s Year: 2005
Pulmonary arterial hypertension (PAH) among end state renal disease (ESRD) patients under chronic hemodyalisis (HD) Source: Eur Respir J 2007; 30: Suppl. 51, 345s Year: 2007
Effects of pulmonary rehabilitation (PR) on arterial stiffness in patients with COPD: The CIROCO study Source: Annual Congress 2011 - Exercise tests and emerging outcomes: defining the impact of pulmonary rehabilitation Year: 2011
Mismatch of major vessel obstruction and pulmonary vascular resistance (PVR) in chronic thromboembolic pulmonary hypertension (CTEPH) with associated medical conditions (AMC) Source: Eur Respir J 2006; 28: Suppl. 50, 402s Year: 2006
HRQoL in adult patients with Eisenmenger syndrome (ES) compared to patients with primary pulmonary hypertension (PPH) or post-embolic pulmonary hypertension (PEPH) Source: Eur Respir J 2002; 20: Suppl. 38, 455s Year: 2002
Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015
Over expression of endothelin-1 (ET-1) in lung fibroblasts (LFb) from patients with pulmonary arterial hypertension (PAH), evidence for loss of inhibitory control Source: International Congress 2016 – New findings in mucosal immunology Year: 2016
Characteristics of idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with connective tissue disease (APAH-CTD) patients in PROSPECT Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013
Hypoxic challenge testing (HCT) in COPD and pulmonary hypertension (PH) Source: Eur Respir J 2004; 24: Suppl. 48, 326s Year: 2004
Relationship between pulmonary hypertension (PH) and lung function in severe COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 252s Year: 2001
Comparison of activities of daily living in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases Year: 2016
Non-invasive parameters can predict out of proportion pulmonary hypertension (PH) in conjunction with heart failure and preserved systolic function (HFPSF) in patients with moderate to severe PH Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010
Arterial concentration of macrophage migration inhibitory factor (MIF) increases with exercise in patients with pulmonary hypertension (PH) Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010
Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009
Features of endothelial dysfunction in patients with COPD in combination with arterial hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 768s Year: 2007
Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016
Impact of borderline (BL) pulmonary hypertension (PH) in chronic lung diseases (CLD). Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020